On Invalid Date, Spyre Therapeutics (NASDAQ: SYRE) reported Q3 2023 earnings per share (EPS) of -$9.34, up 92.98% year over year. Total Spyre Therapeutics earnings for the quarter were -$40.11 million. In the same quarter last year, Spyre Therapeutics's earnings per share (EPS) was -$4.84.
As of Q4 2023, Spyre Therapeutics's earnings has grown year over year. Spyre Therapeutics's earnings in the past year totalled -$294.43 million.
What was SYRE's revenue last quarter?
On Invalid Date, Spyre Therapeutics (NASDAQ: SYRE) reported Q3 2023 revenue of $0.00 up 100% year over year. In the same quarter last year, Spyre Therapeutics's revenue was $174.00 thousand.
What was SYRE's revenue growth in the past year?
As of Q4 2023, Spyre Therapeutics's revenue has grown -81.84% year over year. This is 193.85 percentage points lower than the US Biotechnology industry revenue growth rate of 112.01%. Spyre Therapeutics's revenue in the past year totalled $1.05 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.